Search results for "pharmacogenomic"

showing 10 items of 59 documents

Pharmacogenomics and the treatment of acute myeloid leukemia.

2016

Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous malignancy that is primarily treated with combinations of cytarabine and anthracyclines. Although this scheme remains effective in most of the patients, variability of outcomes in patients has been partly related with their genetic variability. Several pharmacogenetic studies have analyzed the impact of polymorphisms in genes encoding transporters, metabolizers or molecular targets of chemotherapy agents. A systematic review on all eligible studies was carried out in order to estimate the effect of polymorphisms of anthracyclines and cytarabine pathways on efficacy and toxicity of AML treatment. Other emerging gene…

0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentAntineoplastic AgentsBiologyMalignancy03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGeneticsmedicineSNPHumansGenetic variabilityPharmacologyChemotherapyPolymorphism GeneticMyeloid leukemiamedicine.diseaseLeukemia Myeloid Acute030104 developmental biologyPharmacogenetics030220 oncology & carcinogenesisPharmacogenomicsImmunologyCytarabineMolecular MedicinePharmacogeneticsmedicine.drugPharmacogenomics
researchProduct

Pharmacogenomic Characterization and Isobologram Analysis of the Combination of Ascorbic Acid and Curcumin—Two Main Metabolites of Curcuma longa—in C…

2017

ABSTRACT Curcuma longa has long been used in China and India as anti-inflammatory agent to treat a wide variety of conditions. Here we investigated chemoprofiles of three Curcuma species and observed a great variety of phytochemicals with curcumin being among the few present in all three species. On the other hand ascorbic acid (AA) was a compound that was solely found in Curcuma longa. In the present study we explored the cytotoxic effect of a curcumin/AA combination toward human cancer cell lines. The curcumin/AA combination was assessed by isobologram analysis using the Loewe additivity drug interaction model. The drug combination showed additive cytotoxicity towards CCRF-CEM and CEM/ADR…

0301 basic medicinePharmacology03 medical and health scienceschemistry.chemical_compound0302 clinical medicinesynergismGene expressionPharmacology (medical)CurcumaCytotoxicityisobologram analysisOriginal ResearchPharmacologypharmacogenomicsdrug interactionbiologyphytotherapyAscorbic acidbiology.organism_classification030104 developmental biologychemistryCell culture030220 oncology & carcinogenesisABCA1Cancer cellbiology.proteinCurcuminFrontiers in Pharmacology
researchProduct

A Methodological Framework to Discover Pharmacogenomic Interactions Based on Random Forests

2021

The identification of genomic alterations in tumor tissues, including somatic mutations, deletions, and gene amplifications, produces large amounts of data, which can be correlated with a diversity of therapeutic responses. We aimed to provide a methodological framework to discover pharmacogenomic interactions based on Random Forests. We matched two databases from the Cancer Cell Line Encyclopaedia (CCLE) project, and the Genomics of Drug Sensitivity in Cancer (GDSC) project. For a total of 648 shared cell lines, we considered 48,270 gene alterations from CCLE as input features and the area under the dose-response curve (AUC) for 265 drugs from GDSC as the outcomes. A three-step reduction t…

0301 basic medicineRandom ForestsPharmacogenomic Variantsdrug responseGenomicsComputational biologycell linesBiologyQH426-470Article03 medical and health sciences0302 clinical medicineNeoplasmsDrug responseGeneticsHumanscancerGene Regulatory Networksgenomic alterationGenetics (clinical)Random Forestcell linegenomic alterationsTumor tissueRandom forestpharmacogenomic interactions030104 developmental biologyConcordance correlation coefficientDrug Resistance Neoplasm030220 oncology & carcinogenesisPharmacogenomicsIdentification (biology)pharmacogenomic interactions.Cancer cell linesAlgorithmsGenome-Wide Association StudyGenes
researchProduct

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes.

2016

Background: The identification of biomarkers for the estimation of cancer patients’ survival is a crucial problem in modern oncology. Recently, the Affymetrix DMET (Drug Metabolizing Enzymes and Transporters) microarray platform has offered the possibility to determine the ADME (absorption, distribution, metabolism, and excretion) gene variants of a patient and to correlate them with drug-dependent adverse events. Therefore, the analysis of survival distribution of patients starting from their profile obtained using DMET data may reveal important information to clinicians about possible correlations among drug response, survival rate, and gene variants. Methods: In order to provide support …

0301 basic medicinepharmacogenomicoverall survivalBiomedical EngineeringDME genes; genotyping microarrays; overall survival; pharmacogenomics; progression-free survivalBioengineeringBiologyBioinformaticsBiochemistryArticlelcsh:Biochemistrygenotyping microarray03 medical and health sciencesmedicineOverall survivallcsh:QD415-436Progression-free survivalgenotyping microarraysAdverse effectSurvival rateGeneADMEpharmacogenomicsADME geneCancermedicine.diseaseADME genesgenotyping microarrays; ADME genes; pharmacogenomics; overall survival; progression-free survival030104 developmental biologyPharmacogenomicsprogression-free survivalBiotechnologyMicroarrays (Basel, Switzerland)
researchProduct

Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer

2005

Abstract BACKGROUND: Microsatellite instability (MSI) is a biological characteristic of most tumours, being involved in 85% of hereditary non-polyposis colorectal cancer (HNPCC). It also occurs in 10-15% of sporadic colorectal cancers (CRC). HNPCC appears to be caused by germline mutations in mismatch repair (MMR) genes, which are responsible for repairing single base-pair mismatches. MSI is also associated with a better response of CRC to adjuvant chemotherapy with fluoropyrimidines. We investigated any relationship between the MSI status and the TSmRNA expression, the polymorphisms of 5-Fluorouracil (5-FU cellular target, the enzyme thymidylate synthase (TS) and TS expression evaluated by…

AdultAged 80 and overMalePolymorphism GeneticAntibodies MonoclonalThymidylate SynthaseMiddle AgedSettore MED/08 - Anatomia PatologicaImmunohistochemistryGenomic InstabilityHumansFemaleColorectal cancer thymidylate synthase pharmacogenomic microsatellite instability polymorphism molecular therapeutic.RNA Messenger5' Untranslated RegionsColorectal NeoplasmsPromoter Regions GeneticAgedMicrosatellite Repeats
researchProduct

TLR2 and age-related diseases: potential effects of Arg753Gln and Arg677Trp polymorphisms in acute myocardial infarction.

2008

ABSTRACT Inflammation is a key component of immune system. It is involved in both defense and pathophysiological events maintaining the dynamic homeostasis of host organism. Its function is controlled by innate immunity genes. Both their polymorphisms and environmental conditions give rise to different phenotypes in human population. Proinflammatory genotype may be beneficial in early life but not in old people. With advancing age, indeed, it increases the vulnerability and the intensity to inflammatory reactions responsible for the chronic inflammatory diseases, such as atherosclerosis and myocardial infarction (MI). Several studies have looked for detecting a genetic risk profile that mig…

AdultAgingSettore MED/09 - Medicina InternaGenotypePopulationMyocardial InfarctionInflammationPolymorphism Single NucleotideProinflammatory cytokineImmune systemGene FrequencyMedicineHumansMyocardial infarctioneducationSettore MED/04 - Patologia Generaleeducation.field_of_studyInnate immune systembusiness.industryMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareToll-Like Receptor 2TLR2Amino Acid SubstitutionItalyTLR2age-related diseasespolymorphismsacute myocardial infarction.PharmacogenomicsCase-Control StudiesImmunologyGeriatrics and Gerontologymedicine.symptombusinessRejuvenation research
researchProduct

Pro-inflammatory gene variants in myocardial infarction and longevity: implications for pharmacogenomics.

2008

Inflammation and genetics play an important role in the pathogenesis of coronary heart disease (CHD). However, despite the increasing appreciation of the role of genetics in CHD and myocardial infarction (MI) pathogenesis, pharmacogenomic approaches to uncover drug target have not been extensively explored. Cyclo-oxygenases (COXs) and 5-lipoxygenase (5-LO) are the key enzymes in the conversion of arachidonic acid to prostaglandins (PG) and leukotrienes (LT) and are implicated in a wide variety of inflammatory disorders, including atherosclerosis. In fact, PGE2 activates Matrix Metallo-proteinases whereas LTB4 is a chemoactractant for monocytes and activates gene expression in inflammatory c…

AdultMalePathologymedicine.medical_specialtymedia_common.quotation_subjectLongevityMyocardial InfarctionIMMUNOGENETICSINFARCTIONINFLAMMATIONLONGEVITYPHARMACOGENOMICSInflammationDiseaseBioinformaticsPathogenesisYoung AdultDrug Delivery SystemsRisk FactorsDrug DiscoverymedicineHumansGenetic Predisposition to DiseaseMyocardial infarctionAlleleAllelesmedia_commonAged 80 and overInflammationPharmacologyArachidonate 5-Lipoxygenasebusiness.industryAge FactorsLongevityMiddle Agedmedicine.diseasePhenotypeCyclooxygenase 2PharmacogeneticsPharmacogenomicsFemalemedicine.symptombusinessPharmacogenetics
researchProduct

The experience of physicians in pharmacogenomic clinical decision support within eight German university hospitals.

2017

Aim: The aim of this study was to assess the physicians’ attitude, their knowledge and their experience in pharmacogenomic clinical decision support in German hospitals. Materials & methods: We conducted an online survey to address physicians of 13 different medical specialties across eight German university hospitals. In total, 564 returned questionnaires were analyzed. Results: The remaining knowledge gap, the uncertainty of test reimbursement and the physicians’ lack of awareness of existing pharmacogenomic clinical decision support systems (CDSS) are the major barriers for implementing pharmacogenomic CDSS into German hospitals. Furthermore, pharmacogenomic CDSS are most effective …

AdultMalemedicine.medical_specialtyDecision support systemAttitude of Health PersonnelClinical decision support systemGermanHospitals University03 medical and health sciencesYoung Adult0302 clinical medicinePhysiciansSurveys and QuestionnairesGeneticsMedicineHumans030212 general & internal medicineReimbursementAgedPharmacologybusiness.industryMiddle AgedUniversity hospitalDecision Support Systems Clinicallanguage.human_languageTest (assessment)Pharmacogenetics030220 oncology & carcinogenesisPharmacogenomicsFamily medicinelanguageMolecular MedicineFemalebusinessPharmacogenomics
researchProduct

Alzheimer’s disease and genetics of inflammation: a pharmacogenomic vision

2007

Inflammation plays a key role in Alzheimer disease, and dissecting the genetics of inflammation may provide an answer to the possible treatment. The next-generation therapy is based on a pharmacogenomics that will reconure new approaches to a drug used on definite people with specific dosage. The translation of pharmacogenomics into clinical practice will allow bold steps to be taken toward personalized medicine. In response to tissue injury elicited by trauma or infection, the inflammatory response sets in as a complex network of molecular and cellular interactions, directed to facilitate a return to physiological homeostasis and tissue repair. The role of an individual’s genetic backgroun…

Apolipoprotein E2alzheimerInflammationDiseaseAlzheimer DiseaseGeneticsHumansMedicineSettore MED/05 - Patologia ClinicaClinical significancePhysiological HomeostasisInflammationPharmacologyGeneticsSettore MED/04 - Patologia Generalebusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseToll-Like Receptor 4PharmacogeneticsPharmacogenomicsTLR4CytokinesMolecular MedicinePersonalized medicinemedicine.symptomAlzheimer's diseasebusiness
researchProduct

Broad-spectrum Cross-resistance to Anticancer Drugs Mediated by Epidermal Growth Factor Receptor

2019

BACKGROUND The oncogenic role of epidermal growth factor receptor (EGFR) has been intensively studied. However, its emerging role in drug resistance has not been fully addressed. MATERIALS AND METHODS This study systematically investigated the correlation of mRNA and protein expression of EGFR, as well as gene amplification and mutations with the log-transformed half-maximal inhibitory concentration (log10IC50) values obtained from the NCI panel of 60 human tumor cell lines against 83 standard anticancer agents and the top 10 natural cytotoxic products previously screened by us. RESULTS EGFR protein expression, rather than other measurements, was most frequently associated with drug respons…

Cancer ResearchOncogenebiologyChemistryTopoisomeraseAntineoplastic AgentsGeneral MedicineDrug resistanceErbB Receptors03 medical and health sciences0302 clinical medicineOncologyDrug Resistance NeoplasmCell cultureCell Line TumorNeoplasms030220 oncology & carcinogenesisPharmacogenomicsbiology.proteinCancer researchHumansCytotoxic T cellRNA MessengerEpidermal growth factor receptorCross-resistanceAnticancer Research
researchProduct